Atherosclerosis

Cardiovascular
17
Pipeline Programs
14
Companies
24
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
4
0
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 19 programs with unclassified modality

On Market (4)

Approved therapies currently available

U
ALTOPREVApproved
lovastatin
Unknown Company
oral2002
M&
MEVACORApproved
lovastatin
Merck & Co.
oral1987
U
RAMIPRILApproved
ramipril
Unknown Company
oral2015
U
VOSTALLYApproved
ramipril
Unknown Company
Angiotensin Converting Enzyme Inhibitor [EPC]oral2025

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
6 programs
1
extended release niacinPhase 42 trials
Dynalink®-E everolimus-eluting peripheral stentN/A1 trial
ESPRIT BVSN/A1 trial
Endovascular treatment for PADN/A1 trial
Everolimus Eluting BVSN/A1 trial
+1 more programs
Active Trials
NCT00475566Completed104Est. Feb 2010
NCT01468974Completed35Est. Dec 2015
NCT03951727Unknown50Est. May 2022
+4 more trials
M&
Merck & Co.RAHWAY, NJ
3 programs
1
1
1
lovastatinPhase 2/3Small Molecule1 trial
MK0633Phase 21 trial
NiaspanN/A1 trial
Active Trials
NCT00232531Unknown70Est. Feb 2009
NCT00421278Completed180Est. Jan 2007
NCT00116870Completed270Est. Feb 1992
Sanofi
SanofiPARIS, France
1 program
1
RamiprilPhase 4Small Molecule1 trial
Active Trials
NCT01053910Completed1,012
Pfizer
PfizerNEW YORK, NY
1 program
1
Simvastatin or AtorvastatinPhase 4Small Molecule1 trial
Active Trials
NCT00734123Unknown2,948Est. May 2013
DS
Daiichi SankyoChina - Shanghai
2 programs
1
1
Pactimibe sulfatePhase 2/31 trial
PactimibePhase 21 trial
Active Trials
NCT00185146Completed200Est. Aug 2005
NCT00151788Terminated796Est. Mar 2006
Novartis
NovartisBASEL, Switzerland
1 program
1
AliskirenPhase 2/31 trial
Active Trials
NCT01417104Terminated71Est. Jan 2012
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
Micronized 17B-estradiolPhase 2/31 trial
Active Trials
NCT00115024Completed222Est. Nov 1998
BioInvent International
1 program
1
MLDL1278APhase 21 trial
Active Trials
NCT01258907Completed147
R
ResVerlogiXAB - Calgary
1 program
1
RVX000222Phase 21 trial
Active Trials
NCT01058018Completed299Est. Sep 2010
Bristol Myers Squibb
2 programs
1
BMS-844421Phase 11 trial
Blood drawN/A1 trial
Active Trials
NCT00847782Completed150Est. Sep 2009
NCT01082562Terminated40Est. Jul 2010
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
RosuvastatinPhase 1Small Molecule1 trial
Active Trials
NCT00783042Completed80Est. May 2009
Biotronik
BiotronikGermany - Berlin
3 programs
Passeo-18 LuxN/A1 trial
Passeo-18 Lux DRBN/A1 trial
Passeo-18 Lux DRBN/A1 trial
Active Trials
NCT02276313Completed880Est. Jan 2022
NCT01867736Completed72Est. Jul 2014
NCT01221610Completed60Est. Jan 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerSimvastatin or Atorvastatin
Abbottextended release niacin
SanofiRamipril
Abbottextended release niacin
NovartisAliskiren
Daiichi SankyoPactimibe sulfate
Johnson & JohnsonMicronized 17B-estradiol
Merck & Co.lovastatin
BioInvent InternationalMLDL1278A
ResVerlogiXRVX000222
Merck & Co.MK0633
Daiichi SankyoPactimibe
Bristol Myers SquibbBMS-844421
AstraZenecaRosuvastatin
AbbottEndovascular treatment for PAD

Showing 15 of 24 trials with date data

Clinical Trials (24)

Total enrollment: 11,672 patients across 24 trials

NCT00734123PfizerSimvastatin or Atorvastatin

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Start: Apr 2008Est. completion: May 20132,948 patients
Phase 4Unknown
NCT00397657Abbottextended release niacin

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Start: Nov 2006Est. completion: Oct 2009400 patients
Phase 4Terminated
NCT01053910SanofiRamipril

Ramipril 10 mg/Day Prevention

Start: Oct 20031,012 patients
Phase 4Completed
NCT00120289Abbottextended release niacin

Niacin Plus Statin to Prevent Vascular Events

Start: Sep 2005Est. completion: Dec 20123,414 patients
Phase 3Terminated
NCT01417104NovartisAliskiren

Aliskiren Effect on Aortic Plaque Progression

Start: Oct 2009Est. completion: Jan 201271 patients
Phase 2/3Terminated
NCT00151788Daiichi SankyoPactimibe sulfate

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Start: Feb 2004Est. completion: Mar 2006796 patients
Phase 2/3Terminated
NCT00115024Johnson & JohnsonMicronized 17B-estradiol

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

Start: Apr 1994Est. completion: Nov 1998222 patients
Phase 2/3Completed
NCT00116870Merck & Co.lovastatin

MARS - Monitored Atherosclerosis Regression Study

Start: Jun 1985Est. completion: Feb 1992270 patients
Phase 2/3Completed
NCT01258907BioInvent InternationalMLDL1278A

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Start: Mar 2010147 patients
Phase 2Completed
NCT01058018ResVerlogiXRVX000222

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Start: Dec 2009Est. completion: Sep 2010299 patients
Phase 2Completed
NCT00421278Merck & Co.MK0633

The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

Start: Nov 2006Est. completion: Jan 2007180 patients
Phase 2Completed
NCT00185146Daiichi SankyoPactimibe

Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Start: Sep 2002Est. completion: Aug 2005200 patients
Phase 2Completed
NCT01082562Bristol Myers SquibbBMS-844421

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Start: Apr 2010Est. completion: Jul 201040 patients
Phase 1Terminated
NCT00783042AstraZenecaRosuvastatin

Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements

Start: Oct 2008Est. completion: May 200980 patients
Phase 1Completed
NCT03951727AbbottEndovascular treatment for PAD

Stella Supera Siberia

Start: May 2019Est. completion: May 202250 patients
N/AUnknown
NCT02276313BiotronikPasseo-18 Lux

BIOLUX P-III All-Comers Passeo-18 Lux Registry

Start: Oct 2014Est. completion: Jan 2022880 patients
N/ACompleted
NCT01867736BiotronikPasseo-18 Lux DRB

BIOLUX P-II First-in-Man Study to Compare the Passeo-18 Lux DRB Against POBA in Infrapopliteal Arteries

Start: Jul 2012Est. completion: Jul 201472 patients
N/ACompleted
NCT01468974AbbottESPRIT BVS

ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System

Start: Nov 2011Est. completion: Dec 201535 patients
N/ACompleted
NCT01341340AbbottEverolimus Eluting BVS

The ABSORB BTK (Below The Knee) Clinical Investigation

Start: Nov 2011Est. completion: Nov 20122 patients
N/ATerminated
NCT00969865AbbottIndividualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

Start: Oct 2011Est. completion: Dec 2016170 patients
N/ACompleted
NCT01221610BiotronikPasseo-18 Lux DRB

BIOLUX P-I First in Man Study

Start: Oct 2010Est. completion: Jan 201360 patients
N/ACompleted
NCT00847782Bristol Myers SquibbBlood draw

An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism

Start: Mar 2009Est. completion: Sep 2009150 patients
N/ACompleted
NCT00475566AbbottDynalink®-E everolimus-eluting peripheral stent

A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System

Start: May 2007Est. completion: Feb 2010104 patients
N/ACompleted
NCT00232531Merck & Co.Niaspan

Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function

Start: Sep 2004Est. completion: Feb 200970 patients
N/AUnknown

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

14 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)